Market Overview

Xenon Expects XEN801 Results In Q1 2017, Delayed One Quarter


After the close on Wednesday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported Q2 earnings. EPS in the second quarter was a loss of $0.42 versus estimates for a loss of $0.48.

President and CEO Dr. Simon Pimstone spoke about the ongoing Phase 2 clinical trial of XEN801, which was expected to yield topline results in Q4 2016 but has been delayed, saying, "We have now surpassed 50% enrollment in our XEN801 Phase 2 clinical trial in patients with moderate to severe acne, and based on updated projections, we anticipate a read out of top-line results in the first quarter of 2017."

Xenon is slated to present at Canaccord's 36th Annual Growth Conference at 3 .p.m EDT on August 11.

Shares of Xenon Pharmaceuticals closed Wednesday's session down $0.03 or 0.41 percent to $7.36.

Posted-In: Earnings News After-Hours Center


Related Articles (XENE)

View Comments and Join the Discussion!

GoDaddy Misses Earnings, Beats Revenue

Western Union Reports A Slight Beat